



Employee Benefits Webinar Series

# Insights to *Impact*

Elevating Ideas. Empowering Decisions.

HYLANT



# HYLANT

## Benefits Intelligence

Leveraging Data to Optimize Your Health Plan Strategy



**Mark Nixon**

COO, Employee  
Benefits, Hylant

---

**June 10, 2026**


10:00 AM ET

[www.hylant.com](http://www.hylant.com)

# The Challenge – Medical Trend Over Time

Figure 1: PwC medical cost trends, 2007-2026

PwC projects medical cost trend to be 8.5% for Group and 7.5% for Individual in 2026, in line with 8.5% and 7.5% in 2025



Source: PwC analysis

# Using Data to Guide Your Journey

---

Explore

Investigate

Take Action



# Elements of a Data Strategy

## FINANCIAL PERFORMANCE

- Monthly financial package
- Plan costs vs. budget
- High level summary of plan performance
- High claimant status
- YTD results compared to prior years
- IBNR calculations

## CLINICAL INSIGHTS

- Detailed plan analysis
- Clinical insights
- Explorer reports
- Smart cards
- Ad hoc reporting
- Descriptive
- Predictive
- Prescriptive

## PRICE TRANSPARENCY


- Network analysis and comparisons
- Provider study
- Market study
- Population study

## ACTUARIAL ANALYTICS


- Plan value analysis
- Impact of plan design changes
- Migration analysis
- Stop-loss optimization

| Paid Date                      | Jan-24      | Feb-24      | Mar-24      | Apr-24      | May-24      | Jun-24      | Jul-24 | Aug-24 | Sep-24 | Oct-24 | Nov-24 | Dec-24 | Total       | PEPM    |
|--------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|--------|--------|--------|--------|--------|--------|-------------|---------|
| EE Enrollment                  | 882         | 877         | 884         | 884         | 882         | 888         |        |        |        |        |        |        | 5,295       | 883     |
| Member Enrollment              | 2,168       | 2,159       | 2,165       | 2,178       | 2,145       | 2,160       |        |        |        |        |        |        | 12,973      | 2,162   |
| Medical Claims                 | \$1,088,970 | \$857,087   | \$541,774   | \$1,067,487 | \$796,539   | \$725,123   |        |        |        |        |        |        | \$5,075,981 | \$959   |
| Rx Claims                      | \$174,003   | \$187,787   | \$257,312   | \$300,189   | \$212,578   | \$211,907   |        |        |        |        |        |        | \$1,343,755 | \$254   |
| Gross Paid Claims              | \$1,242,974 | \$1,044,874 | \$799,086   | \$1,387,658 | \$1,008,115 | \$937,030   |        |        |        |        |        |        | \$6,419,736 | \$1,212 |
| Rx Rebates                     | \$0         | \$0         | \$0         | \$0         | \$0         | \$0         |        |        |        |        |        |        | \$0         | \$0     |
| Spec Reimbursement             | \$0         | \$0         | \$0         | (\$71,183)  | (\$51,128)  | \$0         |        |        |        |        |        |        | -\$122,311  | -\$23   |
| Net Paid Claims                | \$1,242,974 | \$1,044,874 | \$799,086   | \$1,316,474 | \$956,987   | \$937,030   |        |        |        |        |        |        | \$6,297,425 | \$1,189 |
| Stop Loss Premium              | \$99,003    | \$98,774    | \$99,762    | \$100,207   | \$99,871    | \$99,965    |        |        |        |        |        |        | \$597,383   | \$113   |
| Agg Premium                    | \$3,793     | \$3,771     | \$3,801     | \$3,801     | \$3,793     | \$3,810     |        |        |        |        |        |        | \$22,769    | \$4     |
| Admin & Other                  | \$27,959    | \$27,801    | \$28,023    | \$28,023    | \$27,959    | \$28,088    |        |        |        |        |        |        | \$167,852   | \$32    |
| Total Fixed Costs              | \$130,756   | \$130,348   | \$131,586   | \$132,031   | \$131,423   | \$131,881   |        |        |        |        |        |        | \$788,003   | \$149   |
| Total Plan Cost                | \$1,373,729 | \$1,175,221 | \$930,872   | \$1,448,506 | \$1,088,891 | \$1,068,891 |        |        |        |        |        |        | \$7,085,428 | \$1,338 |
| Expected Budget                | \$1,184,870 | \$1,178,153 | \$1,187,557 | \$1,187,557 | \$1,184,870 | \$1,190,244 |        |        |        |        |        |        | \$7,113,250 | \$1,343 |
| Total Plan Cost vs Budget \$   | \$188,859   | -\$2,932    | -\$256,884  | \$260,948   | -\$96,461   | -\$121,352  |        |        |        |        |        |        | -\$27,822   |         |
| Total Plan Cost as % of Budget | 116%        | 100%        | 78%         | 122%        | 92%         | 90%         |        |        |        |        |        |        | 100%        |         |

# Financial Performance Package




Expected Plan Cost vs Net Plan Cost



|   | Current Year Projection | Current PYTD Annualized Spend | Projection Plan Year |
|---|-------------------------|-------------------------------|----------------------|
| Monthly Enrollment                                    | 538                     | 563                           | 563                  |
| Projected Net Claims PEPM                             | \$1,097                 | \$1,437                       | \$1,570              |
| Fixed Costs PEPM w/ HSA                               | \$325                   | \$325                         | \$352                |
| Plan Spend PEPM                                       | \$1,422                 | \$1,762                       | \$1,922              |
| Annualized Plan Spend                                 | \$9,180,291             | \$11,892,849                  | \$12,987,714         |
| PEPM Δ% From Current Year Projection                  |                         | 24%                           | 35%                  |
| Annualized Plan Spend Δ% From Current Year Projection |                         | 30%                           | 41%                  |

Annualized Plan Spend



- Monthly plan performance
- Year-over-year trends
- Cost drivers
- High-claimant insights
- Budget comparisons
- Forecasts

# Clinical Insights, Not Just Data

---

Your data analytics platform should not only provide claims history, but address what's coming and provide strategies you should consider.



## DESCRIPTIVE (HISTORY)

Reports to help you understand your plan's performance as it evolves throughout the year.



## PREDICTIVE (FUTURE)

Interpretable risk scoring models that identify populations and conditions most likely to adversely impact your plan.



## PRESCRIPTIVE (STRATEGY)

Claims-driven strategies to address your plan's risks, enabling early and effective intervention – improve health outcomes and control costs.


# Descriptive Analytics

- Monthly Plan Performance
- High-Claimant Tracking
- Medical Claims by Diagnosis
- Pharmacy Utilization (\$s and Scripts)
- Chronic Condition Prevalence
- Inpatient Metrics
- Readmissions Reporting
- High-Cost Imaging Usage
- ER Utilization
- Benchmarking
- Preventive Care Screenings
- Procedure/Provider Reporting



# Predictive Analytics

- Interpretable Risk Scoring
- Future Claims Projections
- Risk Prevalence (Diabetes, Obesity, etc.)
- Disease Onset Probability
- Medication Adherence Rates
- Early Intervention Strategies
- Likelihood of Surgery
- High-Risk/Low-Spend Members



**67 members are over 10x more likely than the average member to have a Knee / Hip surgery during the next 12 months**

| Average Probability | Probability | Relative Probability | E           | S           | C           | Grand Total   |
|---------------------|-------------|----------------------|-------------|-------------|-------------|---------------|
| 0.58%               | 0.29%       | 0.5                  | 94.6% (886) | 95.0% (343) | 99.3% (664) | 96.2% (1,893) |
|                     | 0.73%       | 1.3                  | 0.4% (4)    |             | 0.1% (1)    | 0.3% (5)      |
|                     | 4.57%       | 7.9                  | 0.1% (1)    |             |             | 0.1% (1)      |
|                     | 5.26%       | 9.1                  | 0.1% (1)    |             |             | 0.1% (1)      |
|                     | 6.82%       | 11.8                 | 1.5% (14)   | 0.3% (7)    | 0.6% (4)    | 1.0% (19)     |
|                     | 8.38%       | 14.4                 | 2.1% (20)   | 3.6% (13)   |             | 1.7% (33)     |
|                     | 11.70%      | 20.2                 | 1.2% (11)   | 1.1% (4)    |             | 0.8% (15)     |

| Personid  | Plan | Relation | Age Group | Gender | Probability | Relative Probability |
|-----------|------|----------|-----------|--------|-------------|----------------------|
| 11302529  | A04  | S        | 66+       | F      | 11.7%       | 20.2                 |
| 11303378  | A03  | E        | 46-65     | M      | 11.7%       | 20.2                 |
| 11303537  | A04  | E        | 46-65     | M      | 11.7%       | 20.2                 |
| 11304135  | A04  | E        | 46-65     | F      | 11.7%       | 20.2                 |
| 11304172  | A01  | E        | 46-65     | F      | 11.7%       | 20.2                 |
| 11304883  | A01  | E        | 46-65     | F      | 11.7%       | 20.2                 |
| 54771421  | A03  | S        | 46-65     | F      | 11.7%       | 20.2                 |
| 54772812  | A01  | E        | 31-45     | F      | 11.7%       | 20.2                 |
| 54795762  | A01  | E        | 46-65     | F      | 11.7%       | 20.2                 |
| 687487234 | A02  | E        | 46-65     | M      | 11.7%       | 20.2                 |
| 708815333 | A03  | S        | 46-65     | M      | 11.7%       | 20.2                 |
| 713057968 | A01  | S        | 66+       | M      | 11.7%       | 20.2                 |
| 718343743 | A01  | E        | 46-65     | F      | 11.7%       | 20.2                 |
| 76372288  | A02  | E        | 31-45     | F      | 11.7%       | 20.2                 |
| 76399684  | A01  | E        | 46-65     | F      | 11.7%       | 20.2                 |
| 11303152  | A01  | E        | 66+       | F      | 8.4%        | 14.4                 |
| 11303247  | A03  | S        | 46-65     | M      | 8.4%        | 14.4                 |
| 11303284  | A01  | E        | 66+       | F      | 8.4%        | 14.4                 |

MSK Surgery Type:

Legend:  High Surgery Risk,  Low Surgery Risk



Age Group:

Relation:

Gender:

# Prescriptive Analytics

- High-cost drug management opportunities
- Potential for care steerage
- ER redirection opportunities
- Chronic condition management
- Gaps in care
- Potential point solution impact
- Preventive care opportunities



Take Action

**Discuss Rebates with your TPA**

Similar to receiving rebates from your PBM for high-cost prescription drugs, medical rebates can be offered by your TPA to offset costs for expensive drugs administered non-orally through the medical plan. As these procedures become more common, it is important to address the higher costs.

**Pharmacist / Vendor Review and Audit**

By engaging with pharmacists and other experts in the claims validation process, more savings could be achieved. Wasteful provider practices such as "double-dipping" (payment on both the medical and pharmacy plans) can be identified and resolved, resulting in more efficient plan spend.

**Steer Members to Affordable Providers**

Administration of specialty drugs may occur in several different settings. Infusions in the home rather than in a hospital, for example, could provide an additional layer of management and greater predictability in billing. According to one survey, nearly half of payers plan to guide members away from hospital outpatient sites to alternate facilities. Discuss site of care delivery options that could be more cost-effective.

# Strategies Based on Type of Service



## Facility (50%)

- Reference-based pricing (RBP)
- Centers of excellence
- Direct contracts
- Quality of care-based steerage



## Pharmacy (25%)

- Preferred pharmacy agreements
- Specialty Rx management
- Contract language is critical



## Professional (25%)



- Onsite and near-site clinics
- Direct primary care
- Virtual primary care
- Quality of care steerage
- Second-opinion services

# Strategies Based on Spend by Diagnosis

## Review DATA

- Medical spend by diagnosis
- Pharmacy categories by paid amount
- Pharmacy categories by volume
- Chronic condition prevalence
- Adherence metrics

## Sample SPEND



## Potential STRATEGIES

- Population health management
- Condition-specific strategies
- Chronic condition management
- Enhanced primary care benefit
- Second-opinion services



# Start Your Journey - Explore

# Explore Your Trend Drivers

## Medical Total

Select **Medical** or one of its sub-categories to view detailed dashboard

**\$414**<sub>PMPM</sub>  
▲ 6.0%

## Medical

|                        |                        |                       |                        |                        |
|------------------------|------------------------|-----------------------|------------------------|------------------------|
| <b>Inpatient</b>       | <b>Outpatient</b>      | <b>Professional</b>   | <b>ER</b>              | <b>Injectables</b>     |
| <b>\$69</b><br>▼ 12.8% | <b>\$167</b><br>▼ 0.3% | <b>\$80</b><br>▲ 9.5% | <b>\$40</b><br>▲ 42.6% | <b>\$58</b><br>▲ 35.3% |

## Rx Total

Select **Rx** or one of its sub-categories to view detailed dashboard

**\$144**<sub>PMPM</sub>  
▲ 13.6%

## Rx

|                       |                        |                       |
|-----------------------|------------------------|-----------------------|
| <b>Generic</b>        | <b>Brand</b>           | <b>Specialty</b>      |
| <b>\$11</b><br>▲ 9.1% | <b>\$72</b><br>▲ 21.3% | <b>\$62</b><br>▲ 6.6% |

# Medical Explorer: PMPM Costs

Hylant Corporate Group, Inc.



Select to filter

Current Period: **May 2025 - Apr 2026** | Prior Period: **May 2024 - Apr 2025** | **Month Paid** basis  
Division: **All** | Plan: **All** | Person IDs: **All**

Med High Cost Claims Threshold: \$10

## Medical Total

Select **Place of Service** or one of its sub-categories to view detailed dashboard

**\$414**<sub>PMPM</sub>  
▲ 6.0%

## Medical

Inpatient

**\$69**  
▼ 12.8%

Outpatient

**\$167**  
▼ 0.3%

Professional

**\$80**  
▲ 9.5%

ER

**\$40**  
▲ 42.6%

## Top 5 Diagnoses

Select **Diagnosis Chapter** or one of its sub-categories to view detailed dashboard

**\$230**<sub>PMPM</sub>  
▼ 0.8%

55.7% of Medical Total

## Diagnosis Chapter

Neoplasms

**\$67**  
▼ 3.9%

Musculoskeletal System Diseases

**\$55**  
▼ 11.4%

Health Status

**\$47**  
▼ 0.2%

Nervous System Diseases

**\$32**  
▲ 58.5%

# Pharmacy Explorer: PMPM Costs

Hylant Corporate Group, Inc.



Select to filter



Hover over for information

Current Period: **May 2025 - Apr 2026** | Prior Period: **May 2024 - Apr 2025** | Month Paid basis  
 Division: **All** | Plan: **All** | Person IDs: **All**

| Rx Total   | Rx Type   |  |   |
|--|---|--|---|
| <p>Select Rx Type or one of its sub-categories to view detailed dashboard</p> <p><b>\$144</b><sub>PMPM</sub></p> <p>▲13.6%</p> | <p><b>Generic</b></p> <p><b>\$11</b></p> <p>▲9.1%</p> | <p><b>Brand</b></p> <p><b>\$72</b></p> <p>▲21.3%</p> | <p><b>Specialty</b></p> <p><b>\$62</b></p> <p>▲6.6%</p> |

| Top 5 Drug Classes   | Therapeutic Class  |   |  |   |  |
|--|--|---|--|---|--|
| <p>Select Therapeutic Class or one of its sub-categories to view detailed dashboard</p> <p><b>\$86</b><sub>PMPM</sub></p> <p>▲1.7%</p> | <p><b>ADHD/ANTI-NARCOLEPS..</b></p> <p><b>\$22</b></p> <p>▲89.5%</p> | <p><b>ANTIDIABETICS</b></p> <p><b>\$22</b></p> <p>▲3.6%</p> | <p><b>DERMATOLOGICALS</b></p> <p><b>\$21</b></p> <p>▼31.5%</p> | <p><b>ANALGESICS - ANTI-INFLAMMATORY</b></p> <p><b>\$11</b></p> <p>▼49.7%</p> | <p><b>ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES</b></p> <p><b>\$10</b></p> <p>▲11950.6%</p> |

| Top 5 Drugs  | Drug   |  |   |   |  |
|--|--|--|---|---|--|
| <p>Select Drug or one of its sub-categories to view detailed dashboard</p> <p><b>\$50</b><sub>PMPM</sub></p> <p>▲61.6%</p> | <p><b>Stelara</b></p> <p><b>\$14</b></p> <p>▼40.2%</p> | <p><b>Zepbound</b></p> <p><b>\$14</b></p> <p>▲284.6%</p> | <p><b>Mounjaro</b></p> <p><b>\$8</b></p> <p>▲148.6%</p> | <p><b>Kisqali (400 MG Dose)</b></p> <p><b>\$7</b></p> | <p><b>Kesimpta</b></p> <p><b>\$7</b></p> <p>▲1043.6%</p> |



# Hylant Corporate Group, Inc.: Key Metrics

Break down costs by diagnosis chapters and drug classes for selected client against the book of business. All costs are on an allowed basis.

Industry: **All** | Sub-Sector: **All** | Region: **All** | Sub-Region: **All**

Incurred February 2025 - January 2026

Book Size: 155K Members

NAVIGATE



FILTER



EXPORT



- MED & RX**
- KPIs
- CCs & COMPLIANCE

Client: **Hylant Corporate Group, Inc.** Monthly Membership: 1,887

| DIAGNOSIS CHAPTER PMPMs          | CURRENT | BOOK OF BUSINESS |   |
|----------------------------------|---------|------------------|---|
| Neoplasms (Cancer) PMPM          | \$75    | \$68             | ● |
| Musculoskeletal PMPM             | \$65    | \$57             | ● |
| Circulatory Diseases PMPM        | \$18    | \$53             |   |
| Digestive Diseases PMPM          | \$34    | \$42             |   |
| Pregnancy & Childbirth PMPM      | \$26    | \$22             | ● |
| Perinatal Conditions PMPM        | \$13    | \$9              | ● |
| Genitourinary Diseases PMPM      | \$31    | \$32             |   |
| Injury & Poisoning PMPM          | \$41    | \$36             | ● |
| Endocrine System Diseases PMPM   | \$12    | \$16             |   |
| Mental Health PMPM               | \$32    | \$31             | ● |
| Infectious Diseases PMPM         | \$4     | \$12             |   |
| Nervous System Diseases PMPM     | \$37    | \$23             | ● |
| Respiratory System Diseases PMPM | \$11    | \$18             |   |

| DRUG CLASS PMPMs       | CURRENT | BOOK OF BUSINESS |   |
|------------------------|---------|------------------|---|
| Rx Allowed PMPM        | \$176   | \$193            |   |
| Antidiabetics PMPM     | \$22    | \$40             |   |
| Dermatologicals PMPM   | \$30    | \$30             | ● |
| Anti-Inflammatory PMPM | \$17    | \$22             |   |
| Antivirals PMPM        | \$3     | \$6              |   |
| Mental Health Rx PMPM  | \$11    | \$12             |   |
| Antineoplastics PMPM   | \$9     | \$13             |   |
| Anti-Obesity/ADHD PMPM | \$27    | \$10             | ● |
| Hematological PMPM     | \$0     | \$2              |   |

CONFIDENTIAL: This report and the contents within it are confidential and intended solely for the use of the individuals with access granted to them, and should not be distributed beyond the individuals without the express written consent of MultiPlan's Data & Decision Science team.



# Hylant Corporate Group, Inc.: Key Metrics

Explore medical, pharmacy, and other target KPIs for selected client against the book of business. Click on a metric to view associated report(s).

Industry: All | Sub-Sector: All | Region: All | Sub-Region: All

Incurred February 2025 - January 2026

Book Size: 155K Members

NAVIGATE



FILTER



EXPORT



MED & RX

KPIs

CCs & COMPLIANCE

Client: Hylant Corporate Group, Inc. Monthly Membership: 1,887

| MEDICAL KPIs                      | CURRENT | BOOK OF BUSINESS |   |
|-----------------------------------|---------|------------------|---|
| ER Visits per 1000                | 206.7   | 264.2            |   |
| Non-Emergent ER Visits per 1000   | 94.3    | 108.7            |   |
| IP Visits per 1000                | 39.2    | 61.2             |   |
| Urgent Care Visits per 1000       | 291.5   | 251.2            | ● |
| Adult Preventive Visits per 1000* | 1,148.8 | 809.5            | ● |
| Deliveries per 1000*              | 62.5    | 46.9             | ● |
| C-Section Rate                    | 23.3%   | 32.7%            |   |
| Asthma Adverse Events per 1000    | 29.4    | 82.8             |   |
| Cardio Adverse Events per 1000    | 556.8   | 801.3            |   |
| Diabetes Adverse Events per 1000  | 39.6    | 52.6             |   |
| Dialysis Allowed/Claim            |         | \$2,121          |   |
| Injectables (J Code) PMPM         | \$59    | \$42             | ● |
| Telehealth Visit Rate             | 9.9%    | 5.8%             |   |

| RX KPIs                        | CURRENT | BOOK OF BUSINESS |   |
|--------------------------------|---------|------------------|---|
| Specialty Rx PMPM              | \$77    | \$93             |   |
| Non-Specialty Rx PMPM          | \$99    | \$100            |   |
| Rx Scripts per Member          | 9.1     | 11.1             |   |
| Weight Loss (GLP-1) Drugs PMPM | \$34    | \$32             | ● |
| Brand w/ Generic PMPM          | \$9     | \$5              | ● |
| Substitutable Rx PMPM          | \$1     | \$1              |   |
| OTHER KPIs                     |         |                  |   |
| % High Risk Members            | 7.7%    | 7.4%             | ● |
| HCC over \$100k per 1000       | 11.7    | 12.8             |   |
| HCC over \$50k per 1000        | 28.6    | 32.6             |   |
| % Child Bearing Female Members | 25.5%   | 22.9%            | ● |
| Average Contract Size          | 2.12    | 1.90             | ● |
| Member OOP %                   | 18.2%   | 14.1%            |   |
| OON OOP Member %               | 66.7%   | 18.6%            |   |

CONFIDENTIAL: This report and the contents within it are confidential and intended solely for the use of the individuals with access granted to them, and should not be distributed beyond the individuals without the express written consent of MultiPlan's Data & Decision Science team.



# Hylant Corporate Group, Inc.: Key Metrics

Explore specific Chronic Condition and Compliance KPIs for selected client against book of business. Click on a metric to view associated report(s).

Industry: All | Sub-Sector: All | Region: All | Sub-Region: All

Incurring February 2025 - January 2026

Book Size: 155K Members

NAVIGATE



FILTER



EXPORT



MED & RX    KPIs    **CCs & COMPLIANCE**

Client: Hylant Corporate Group, Inc. Monthly Membership: 1,887

| PREVALENCE                   | CURRENT | BOOK OF BUSINESS | AVG COST                               | CURRENT  | BOOK OF BUSINESS | COMPLIANCE RATE              | CURRENT | BOOK OF BUSINESS |
|------------------------------|---------|------------------|--|----------|------------------|------------------------------|---------|------------------|
| Cancer Prevalence %          | 8.9%    | 5.1%             | Avg Cost of Members w/ Cancer          | \$33,527 | \$51,330         | Adult Preventive Care        | 64.4%   | 48.7%            |
| Depression Prevalence %      | 11.5%   | 10.3%            | Avg Cost of Members w/ Depression      | \$13,458 | \$13,510         | Breast Cancer Screening      | 81.2%   | 69.0%            |
| Diabetes Prevalence %        | 4.3%    | 8.2%             | Avg Cost of Members w/ Diabetes        | \$20,415 | \$22,221         | Cervical Cancer Screening    | 72.2%   | 55.0%            |
| Hypertension Prevalence %    | 9.7%    | 12.4%            | Avg Cost of Members w/ Hypertension    | \$20,727 | \$22,789         | Colon Cancer Screening       | 67.6%   | 49.1%            |
| Low Back Pain Prevalence %   | 2.4%    | 2.7%             | Avg Cost of Members w/ Low Back Pain   | \$20,726 | \$22,487         | Prostate Cancer Screening    | 74.4%   | 57.4%            |
| Obesity Prevalence %         | 8.9%    | 9.1%             | Avg Cost of Members w/ Obesity         | \$18,951 | \$16,841         | Diabetes HbA1c Screening     | 88.0%   | 89.6%            |
| Substance Abuse Prevalence % | 3.5%    | 4.6%             | Avg Cost of Members w/ Substance Abuse | \$16,657 | \$32,921         | Diabetes Med Adherence       | 67.7%   | 61.5%            |
|                              |         |                  |  |          |                  | Hyperlipidemia Med Adherence | 43.8%   | 44.2%            |
|                              |         |                  |  |          |                  | Hypertension Med Adherence   | 55.9%   | 48.3%            |

CONFIDENTIAL: This report and the contents within it are confidential and intended solely for the use of the individuals with access granted to them, and should not be distributed beyond the individuals without the express written consent of MultiPlan's Data & Decision Science team.

# High Cost Claimant Cohort

## HIGH COST CLAIMANT KEY INDICATORS

\*High Risk Employees / Members represent Employees / Members who fall into either risk score category 4 or 5.

% NEW HCCs

**66.7%**

33.3%  
Repeat HCCs

HIGH RISK\* MEMBERS

**90.5%**

▼ 9.5%  
From Prior Period

% WITH CHRONIC CONDITIONS

**90.5%**

▼ 0.4%  
From Prior Period

ER VISITS PER 1000 HCCs

**2,000.0**

▲ 223.1%  
From Prior Period

IP VISITS PER 1000 HCCs

**381.0**

▼ 53.4%  
From Prior Period



## TOP DIAGNOSIS CHAPTERS / THERAPEUTIC CLASSES

■ BELOW AVG ■ ABOVE AVG

| Diagnosis/Drug Class                     | # HCCs | Total Cost | PMPM        |
|--|--------|------------|-------------|
| Neoplasms                                | 11     | \$1.11M    | (\$48 PMPM) |
| Nervous System Diseases                  | 10     | \$397K     | (\$17 PMPM) |
| Injury & Poisoning                       | 8      | \$376K     | (\$16 PMPM) |
| DERMATOLOGICALS                          | 11     | \$326K     | (\$14 PMPM) |
| Musculoskeletal System Diseases          | 16     | \$271K     | (\$12 PMPM) |
| ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES | 4      | \$233K     | (\$10 PMPM) |
| GASTROINTESTINAL AGENTS - MISC.          | 4      | \$179K     | (\$8 PMPM)  |
| Mental and Behavioral Health             | 11     | \$158K     | (\$7 PMPM)  |
| Perinatal Conditions                     | 1      | \$147K     | (\$6 PMPM)  |
| Symptoms & Signs                         | 17     | \$138K     | (\$6 PMPM)  |

## TOP PROVIDERS

■ BELOW AVG ■ ABOVE AVG

| Provider Name                                    | Med/Rx | # HCCs | Total Cost | PMPM        |
|--|--------|--------|------------|-------------|
| PRIME THERAPEUTICS PHARMACY LLC                  | RX     | 10     | \$781K     | (\$34 PMPM) |
| INDIANA UNIVERSITY HEALTH, INC                   | MED    | 2      | \$335K     | (\$15 PMPM) |
| MERCY HEALTH - ST VINCENT MEDICAL CENTER LLC     | MED    | 4      | \$331K     | (\$14 PMPM) |
| MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES | MED    | 1      | \$249K     | (\$11 PMPM) |
| CENTRAL FLORIDA REGIONAL HOSPITAL, INC           | MED    | 1      | \$218K     | (\$9 PMPM)  |
| INDIANA UNIVERSITY HEALTH INC                    | MED    | 3      | \$181K     | (\$8 PMPM)  |
| THE CLEVELAND CLINIC FOUNDATION                  | MED    | 6      | \$171K     | (\$7 PMPM)  |
| UNIVERSITY OF VERMONT MEDICAL CENTER INC         | MED    | 1      | \$146K     | (\$6 PMPM)  |
| ILICIA SHUGARMAN                                 | MED    | 1      | \$129K     | (\$6 PMPM)  |
| BIERMAN ABA INC.                                 | MED    | 1      | \$117K     | (\$5 PMPM)  |

## TOP PROCEDURES

■ BELOW AVG ■ ABOVE AVG

| Procedure Category  | # HCCs | Total Cost | PMPM        |
|---|--------|------------|-------------|
| Null  | 20     | \$102K     | (\$43 PMPM) |
| Radiology   | 19     | \$314K     | (\$14 PMPM) |
| Medicine  | 21     | \$284K     | (\$12 PMPM) |
| Aggregate per diem  | 2      | \$233K     | (\$10 PMPM) |
| Pre-MDC   | 1      | \$218K     | (\$9 PMPM)  |
| Diseases & Disorders of the Musculoskeletal System & Connective Tissue    | 2      | \$163K     | (\$7 PMPM)  |
| Newborns & Other Neonates with Conditions Originating in Perinatal Period | 1      | \$144K     | (\$6 PMPM)  |
| Evaluation and Management   | 21     | \$140K     | (\$6 PMPM)  |
| Surgery   | 20     | \$121K     | (\$5 PMPM)  |
| Unspecified   | 6      | \$4K       | (\$0 PMPM)  |



# Investigate Pharmacy (and take action)

# Pharmacy Explorer: PMPM Costs

Hylant Corporate Group, Inc.

Select to filter

Hover over for information

Current Period: May 2025 - Apr 2026 | Prior Period: May 2024 - Apr 2025 | Month Paid basis  
 Division: All | Plan: All | Person IDs: All

| Rx Total   | Rx Type   |  |   |
|--|---|--|---|
| <p>Select Rx Type or one of its sub-categories to view detailed dashboard</p> <p><b>\$144</b><sub>PMPM</sub></p> <p>▲13.6%</p> | <p><b>Generic</b></p> <p><b>\$11</b></p> <p>▲9.1%</p> | <p><b>Brand</b></p> <p><b>\$72</b></p> <p>▲21.3%</p> | <p><b>Specialty</b></p> <p><b>\$62</b></p> <p>▲6.6%</p> |

| Top 5 Drug Classes   | Therapeutic Class  |   |  |   |  |
|--|--|---|--|---|--|
| <p>Select Therapeutic Class or one of its sub-categories to view detailed dashboard</p> <p><b>\$86</b><sub>PMPM</sub></p> <p>▲1.7%</p> | <p><b>ADHD/ANTI-NARCOLEPS..</b></p> <p><b>\$22</b></p> <p>▲89.5%</p> | <p><b>ANTIDIABETICS</b></p> <p><b>\$22</b></p> <p>▲3.6%</p> | <p><b>DERMATOLOGICALS</b></p> <p><b>\$21</b></p> <p>▼31.5%</p> | <p><b>ANALGESICS - ANTI-INFLAMMATORY</b></p> <p><b>\$11</b></p> <p>▼49.7%</p> | <p><b>ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES</b></p> <p><b>\$10</b></p> <p>▲11950.6%</p> |

| Top 5 Drugs  | Drug   |  |   |   |  |
|--|--|--|---|---|--|
| <p>Select Drug or one of its sub-categories to view detailed dashboard</p> <p><b>\$50</b><sub>PMPM</sub></p> <p>▲61.6%</p> | <p><b>Stelara</b></p> <p><b>\$14</b></p> <p>▼40.2%</p> | <p><b>Zepbound</b></p> <p><b>\$14</b></p> <p>▲284.6%</p> | <p><b>Mounjaro</b></p> <p><b>\$8</b></p> <p>▲148.6%</p> | <p><b>Kisqali (400 MG Dose)</b></p> <p><b>\$7</b></p> | <p><b>Kesimpta</b></p> <p><b>\$7</b></p> <p>▲1043.6%</p> |



# Rx Trend Decomposition

Time Period: May 2022 - Dec 2025 (Paid)

Hylant Corporate Group, Inc.



Plan Paid/Allowed: **Plan Paid** | Enrollment by: **Member** | Incurred/Paid Date: **Paid** | Rebates: **Excluded** | Division: **All** | Plan: **All**



\*Unit Cost = Plan Paid per Quantity Dispensed, Utilization = Quantity Dispensed per 1000 Members

\*\*Per Member Metrics Exclude Rx rebates



# Top Drug Classes by Plan Paid

Hylant Corporate Group, Inc.

Plan Paid/Allowed: **Plan Paid** | Incurred/Paid Date: **Paid** | Division: **All** | Plan: **All**

Time Period: May 2022 - Dec 2025 (Paid)

Select Costs Metric:

Cost per 30-Day Supply

Highlight Classes w/ Metric Over:


\$500



Plan Paid and Script Count Over Time

Select a Drug Class to filter

| Rank | Drug Class                       | Plan Paid | Script Count | Cost per 30-Day Supply Claimants |
|------|----------------------------------|-----------|--------------|----------------------------------|
| 1    | DERMATOLOGICALS                  | \$2,097K  | 2,363        | \$941                            |
| 2    | ANTIDIABETICS                    | \$1,624K  | 2,905        | \$343                            |
| 3    | ANALGESICS - ANTI-INFLAMMATORY   | \$1,260K  | 1,657        | \$697                            |
| 4    | ADHD/ANTI-NARCOLEPSY/ANTI-OBES.. | \$1,037K  | 3,377        | \$288                            |
| 5    | ANTICOAGULANTS                   | \$374K    | 625          | \$443                            |
| 6    | ANTIASTHMATIC AND BRONCHODILA..  | \$365K    | 2,345        | \$120                            |
| 7    | ENDOCRINE AND METABOLIC AGENT..  | \$352K    | 241          | \$723                            |
| 8    | MIGRAINE PRODUCTS                | \$315K    | 791          | \$412                            |
| 9    | PSYCHOTHERAPEUTIC AND NEUROL..   | \$294K    | 188          | \$1,340                          |
| 10   | ANTINEOPLASTICS AND ADJUNCTIVE.. | \$240K    | 369          | \$350                            |
| 11   | MEDICAL DEVICES AND SUPPLIES     | \$216K    | 568          | \$196                            |
| 12   | MISCELLANEOUS THERAPEUTIC CLA..  | \$196K    | 120          | \$1,275                          |
| 13   | GASTROINTESTINAL AGENTS - MISC.  | \$193K    | 197          | \$806                            |
| 14   | VACCINES                         | \$141K    | 1,640        | \$2,075                          |
| 15   | HEMATOLOGICAL AGENTS - MISC.     | \$137K    | 84           | \$685                            |
| 16   | CONTRACEPTIVES                   | \$128K    | 1,891        | \$34                             |
| 17   | ANTIDEPRESSANTS                  | \$111K    | 6,308        | \$9                              |
| 18   | ANTICONVULSANTS                  | \$79K     | 1,562        | \$33                             |
| 19   | ANTIPSYCHOTICS/ANTIMANIC AGENT.. | \$78K     | 443          | \$125                            |
| 20   | OPHTHALMIC AGENTS                | \$73K     | 798          | \$104                            |



# Top Drugs by Plan Paid

Time Period: May 2022 - Dec 2025 (Paid)

## Hylant Corporate Group, Inc.



Plan Paid/Allowed: **Plan Paid** | Incurred/Paid Date: **Paid** | Division: **All** | Plan: **All**


Highlight Drugs w/ Unit Cost Over:

**\$3,000**

| Rank | Drug                 | Drug Class                    | Rx Type   | Plan Paid | Script Count | Unit Cost<br>(Cost/Quantity Disp) | Claimants |
|------|----------------------|-------------------------------|-----------|-----------|--------------|-----------------------------------|-----------|
| 1    | Stelara              | DERMATOLOGICALS               | Specialty | \$1,710K  | 67           | \$26,927                          | 4         |
| 2    | Wegovy               | ADHD/ANTI-NARCOLEPSY/ANTI-..  | Brand     | \$453K    | 362          | \$475                             | 49        |
| 3    | Humira (2 Pen)       | ANALGESICS - ANTI-INFLAMMAT.. | Specialty | \$387K    | 55           | \$3,522                           | 4         |
| 4    | Zepbound             | ADHD/ANTI-NARCOLEPSY/ANTI-..  | Brand     | \$310K    | 359          | \$424                             | 45        |
| 5    | Rinvoq               | ANALGESICS - ANTI-INFLAMMAT.. | Specialty | \$252K    | 42           | \$200                             | 3         |
| 6    | Eliquis              | ANTICOAGULANTS                | Brand     | \$244K    | 395          | \$9                               | 28        |
| 7    | Ozempic (1 MG/D..    | ANTIDIABETICS                 | Brand     | \$225K    | 209          | \$304                             | 20        |
| 8    | Jardiance            | ANTIDIABETICS                 | Brand     | \$222K    | 335          | \$17                              | 21        |
| 9    | Norditropin FlexPro  | ENDOCRINE AND METABOLIC A..   | Specialty | \$216K    | 25           | \$1,288                           | 2         |
| 10   | Mounjaro             | ANTIDIABETICS                 | Brand     | \$212K    | 206          | \$508                             | 24        |
| 11   | Xeljanz              | ANALGESICS - ANTI-INFLAMMAT.. | Specialty | \$190K    | 39           | \$81                              | 1         |
| 12   | Humira Pen           | ANALGESICS - ANTI-INFLAMMAT.. | Specialty | \$177K    | 26           | \$3,404                           | 3         |
| 13   | Otezla               | ANALGESICS - ANTI-INFLAMMAT.. | Specialty | \$161K    | 36           | \$74                              | 1         |
| 14   | Kesimpta             | PSYCHOTHERAPEUTIC AND NE..    | Specialty | \$144K    | 17           | \$19,002                          | 2         |
| 15   | Ozempic (0.25 or 0.. | ANTIDIABETICS                 | Brand     | \$131K    | 143          | \$325                             | 29        |
| 16   | Revlimid             | MISCELLANEOUS THERAPEUTIC..   | Specialty | \$130K    | 8            | \$775                             | 1         |
| 17   | Xarelto              | ANTICOAGULANTS                | Brand     | \$128K    | 161          | \$17                              | 10        |
| 18   | Trulicity            | ANTIDIABETICS                 | Brand     | \$125K    | 135          | \$462                             | 10        |
| 19   | Tavalisse            | HEMATOLOGICAL AGENTS - MIS..  | Specialty | \$122K    | 11           | \$185                             | 1         |
| 20   | Aubagio              | PSYCHOTHERAPEUTIC AND NE..    | Specialty | \$121K    | 16           | \$252                             | 1         |

Plan Paid and Scripts Over Time

Select a Drug to filter



# Explore Supporting Data


## INJECTABLES VS SPECIALTY PHARMACY

Average By  
Member


# \$60

Injectables Allowed PMPM  
Current Period

- ▲ \$14 vs PY (▲ 30.9%)
- ▲ \$20 from benchmark (▲ 48.1%)



### Injectable Allowed PMPM May 2024 - Apr 2026



# MEDICAL INJECTABLES COST BREAKDOWN Current Period

Cost Basis

Per Claim

## Procedure Allowed Per Claim

Select a Procedure to filter.

| Cpt Code | Procedure Name               | Claims | Allowed Per Claim |
|----------|------------------------------|--------|-------------------|
| J2350    | INJECTION, OCRELIZUMAB, 1 MG | 2      | \$35,541          |
| J2327    | INJ RISANKIZUMAB-RZAA 1 MG   | 2      | \$21,434          |
| J1561    | GAMUNEX-C/GAMMAKED           | 21     | \$13,705          |
| J9144    | DARATUMUMAB, HYALURONIDASE   | 18     | \$8,469           |
| J9316    | PERTUZU, TRASTUZU, 10 MG     | 20     | \$8,415           |
| J1559    | HIZENTRA INJECTION           | 15     | \$8,372           |
| J2353    | OCTREOTIDE INJECTION, DEPOT  | 14     | \$7,818           |
| J0491    | INJ ANIFROLUMAB-FNIA 1MG     | 27     | \$6,326           |
| J3240    | THYROTROPIN INJECTION        | 2      | \$4,963           |
| J0129    | ABATACEPT INJECTION          | 12     | \$4,426           |

## Location Allowed Per Claim

Select a Location to filter.

| Service Location                      | Claims | Allowed Per Claim |
|---------------------------------------|--------|-------------------|
| PATIENT'S HOME (NOT AS HOME HEALTH .. | 43     | \$9,845           |
| OUTPATIENT - OTHER THAN EMERGENCY ..  | 123    | \$1,922           |
| OFFICE, CLINIC, OR MEDICAL CENTER     | 447    | \$1,548           |
| OUTPATIENT - SURGERY CENTER           | 5      | \$139             |
| OUTPATIENT - SURGERY RELATED          | 205    | \$121             |
| OUTPATIENT - EMERGENCY (NOT POLICY .. | 198    | \$44              |
| OUTPATIENT - SERVICES AND PROCEDUR..  | 1      | \$4               |
| OUTPATIENT - URGENT CARE              | 42     | \$4               |
| NO POS NEEDED FOR TOS                 | 1      | \$0               |
| INPATIENT - SERVICES AND PROCEDURES   | 0      | \$0               |

## Provider Allowed Per Claim

Select a Provider to filter.

| Provider NPI | Provider Name            | State | Claims | Allowed Per Claim |
|--------------|--------------------------|-------|--------|-------------------|
| 1215015870   | TIMOTHY CARRABINE        | OH    | 2      | \$35,541          |
| 1619946746   | INDIANA UNIVERSITY HEA.. | IN    | 24     | \$12,844          |
| 1790763985   | JENNIFER MULLER          | FL    | 2      | \$11,419          |
| 1366425209   | SUSAN MORGAN             | FL    | 1      | \$11,239          |
| 1891701082   | MOHAMMED IBRAHIM         | MI    | 1      | \$10,607          |
| 1104230176   | SOLEO HEALTH INC.        | AZ    | 5      | \$10,379          |
| 1568492916   | INDIANA UNIVERSITY HEA.. | IN    | 2      | \$9,173           |
| 1548206410   | INDIANA UNIVERSITY HEA.. | IN    | 1      | \$8,906           |
| 1659506319   | Multiple Providers       | FL    | 16     | \$8,463           |
| 1255610473   | DANIEL KOBRINSKI         | FL    | 4      | \$8,376           |
|              |                          | IL    | 0      | \$0               |
| 1639198450   | JOSEPH GIBBONS           | OH    | 3      | \$8,011           |
| 1083607089   | VIVEK ABHYANKAR          | OH    | 6      | \$7,819           |

## Person/Procedure Allowed Per Claim



Select a Person ID to filter.

| Person ID | Procedure Name               | Claims | Allowed Per Claim |
|-----------|------------------------------|--------|-------------------|
| 76488779  | INJECTION, OCRELIZUMAB, 1 MG | 2      | \$35,541          |
| 11303850  | HIZENTRA INJECTION           | 3      | \$27,257          |
| 687487226 | INJ RISANKIZUMAB-RZAA 1 MG   | 2      | \$21,434          |
| 11303850  | GAMUNEX-C/GAMMAKED           | 13     | \$16,576          |
| 11303868  | DARATUMUMAB, HYALURONIDA..   | 7      | \$11,359          |
| 11303846  | GAMUNEX-C/GAMMAKED           | 8      | \$9,039           |
| 54774644  | PERTUZU, TRASTUZU, 10 MG     | 20     | \$8,415           |
| 11303096  | OCTREOTIDE INJECTION, DEPOT  | 14     | \$7,818           |
| 11303450  | INJ ANIFROLUMAB-FNIA 1MG     | 13     | \$7,784           |
| 11304123  | DARATUMUMAB, HYALURONIDA..   | 11     | \$6,629           |
| 76120947  | INJ ANIFROLUMAB-FNIA 1MG     | 14     | \$4,972           |
| 11303868  | THYROTROPIN INJECTION        | 2      | \$4,963           |
| 76389611  | ABATACEPT INJECTION          | 12     | \$4,426           |

# Explore Supporting Data

## GLP-1 WEIGHT LOSS DRUGS IMPACT Current Period

Obesity / Diabetes Flag  Lag (months)



### Members on GLP-1 Weight Loss Drugs

Members Categorized based on ICD flags on latest 24 months prior to Apr 2026



|          |               | Claimants | % of Claimants | Amount Allowed | % of Allowed |
|----------|---------------|-----------|----------------|----------------|--------------|
| Both     | ANTI-OBESITY  | 8         | 9%             | \$77,297       | 10%          |
|          | ANTIDIABETICS | 16        | 17%            | \$148,183      | 19%          |
| Diabetic | ANTIDIABETICS | 18        | 20%            | \$128,256      | 16%          |
| Obese    | ANTI-OBESITY  | 39        | 42%            | \$357,792      | 45%          |
|          | ANTIDIABETICS | 1         | 1%             | \$958          | 0%           |
| Neither  | ANTI-OBESITY  | 10        | 11%            | \$73,953       | 9%           |
|          | ANTIDIABETICS | 1         | 1%             | \$1,095        | 0%           |

|                                      |  |  |   |                               |   |
|--------------------------------------|--|--|---|-------------------------------|---|
| Claimants<br>92<br>▲39.4% from prior | Amount Allowed<br>\$787,534<br>▲58.7% from prior | Allowed per 30-day Supply<br>\$1,186<br>▼3.1% from prior | Allowed per Quantity Dispensed<br>\$476<br>▲6.8% from prior | Potential Savings<br>\$76,984 | Benchmark PMPM<br>\$34<br>▲19% from prior |
|--------------------------------------|--|--|---|-------------------------------|---|

\*Benchmark reflects rolling-12 values even if different time period is selected above

## COHORT OVERVIEW - Med + GLP-1 Claims

Use filters and parameters to alter cohort analysis. These only apply to this section and will not update the other aspects of the report.  
Cohort only includes members on a plan at least 24 months prior to Apr 2026.



### Cohort Selection and Filters:

Cohort Claims Metric

Set Min Days Supply on GLP-1? \*

Minimum GLP-1 Days Supply \*

Cohort Analyzed

HCC Indicator

HCC Threshold

\*Setting the minimum days to True will place members who have not filled GLP-1 drugs for specified number of days in the "No GLP-1 cohort" for comparison purposes. If set to False, anyone who has at least 1 fill of a GLP-1 will be classified as a GLP-1 claimant. Default set to 84 days which is a 3-month supply.



# Investigate Medical (and take action)

# Medical Explorer: PMPM Costs

Hylant Corporate Group, Inc.



Select to filter

Current Period: **May 2025 - Apr 2026** | Prior Period: **May 2024 - Apr 2025** | **Month Paid** basis

Division: **All** | Plan: **All** | Person IDs: **All**

Med High Cost Claims Threshold: \$10

## Medical Total

Select **Place of Service** or one of its sub-categories to view detailed dashboard

**\$414**<sub>PMPM</sub>

▲ 6.0%

## Medical

**Inpatient**

**\$69**

▼ 12.8%

**Outpatient**

**\$167**

▼ 0.3%

**Professional**

**\$80**

▲ 9.5%

**ER**

**\$40**

▲ 42.6%

## Top 5 Diagnoses

Select **Diagnosis Chapter** or one of its sub-categories to view detailed dashboard

**\$230**<sub>PMPM</sub>

▼ 0.8%

55.7% of Medical Total

## Diagnosis Chapter

**Neoplasms**

**\$67**

▼ 3.9%

**Musculoskeletal System Diseases**

**\$55**

▼ 11.4%

**Health Status**

**\$47**

▼ 0.2%

**Nervous System Diseases**

**\$32**


▲ 58.5%

# Explore Supporting Data


## ER VISITS PER 1000 MEMBERS

Select an emergency status below to filter the data elements in the entire report.


Lag:  Frequent Utilizer Status:  HCC Threshold:




ER Visits per 1000 - May 2024 - Apr 2026 w/ 2 month lag



### Top Diagnoses for ER Visits Current 12 Months




### Top Emergency Room Locations Current 12 Months



Multi Year Diagnosis compare

Diag Lookback | Sheet 1 | View: Original | Save Custom View | Watch



**Date**  
■ 2025  
■ 2024  
■ 2023

**Spend Type**  
 Allowed

**N Months Ending**  
 December 2025

**Rank Top N**  
 10

**N Month Lookback**  
 36

**Date Choice**  
 Plan Year

# Explore Supporting Data

## DISEASES OF THE MUSCULOSKELETAL SYSTEM TREND Medical claims only

MSK Allowed PMPM


**\$70**

Current Period ending Apr 2026

▼9% from prior period

▲21% from benchmark current period

■ Current Period   ■ Prior Period   ■ Benchmark




## MUSCULOSKELETAL RANK AMONG TOP DIAGNOSES

Top Medical ICD Chapters Current 12 months

| Rank | ICD Chapter  | Amount Allowed | Claimants | Allowed PMPM |
|------|--|----------------|-----------|--------------|
| 1    | Neoplasms  | \$1,673,227    | 313       | \$104.67     |
| 2    | Diseases of the musculoskeletal system and connective tissue | \$1,604,456    | 581       | \$80.81      |
| 3    | Diseases of the digestive system                             | \$809,696      | 221       | \$64.60      |
| 4    | Certain conditions originating in the perinatal period       | \$298,765      | 56        | \$57.77      |

■ Diseases of the musculoskeletal system and connective tissue  
■ Other



Demographics Current Period

|                      | E         | S         | C        |
|----------------------|-----------|-----------|----------|
| Claimants            | 329       | 153       | 100      |
| % of Claimants       | 56.6%     | 26.3%     | 17.2%    |
| Amount Allowed       | \$941,730 | \$579,395 | \$83,331 |
| Allowed PMPM Current | \$52      | \$43      | \$9      |
| Allowed per Claimant | \$2,862   | \$3,787   | \$833    |

# Chronic Conditions Category Summary

PMPM view

Claims Cost By

Category Claims

Claim Cost Type

Amount Allowed

Rolling 12-Month Comparison

May 2025 through Apr 2026

Division: All

## CHRONIC CONDITIONS CATEGORY DETAILS

Sort By

Members

Prevalence

All Members

| Curr Rank | Prev Rank | Condition Category                          | Amount Allowed              | % Avg Prevalence<br>(Avg Prevalence - All Members) |
|-----------|-----------|---|-----------------------------|--|
| 3         | 3         | Mental Health                               | \$408,972<br>(\$79 PMPM)    | 2.59%<br>(433)                                     |
| 11        | 8         | Hypertension                                | \$56,121<br>(\$20 PMPM)     | 1.37%<br>(229)                                     |
| 10        | 9         | Diabetes                                    | \$65,503<br>(\$27 PMPM)     | 1.20%<br>(201)                                     |
| 26        | 27        | Obesity                                     | \$7,524<br>(\$4 PMPM)       | 1.02%<br>(171)                                     |
| 2         | 2         | RA/OA (Rheumatoid Arthritis/Osteoarthritis) | \$446,387<br>(\$222 PMPM)   | 1.00%<br>(167)                                     |
| 21        | 25        | Hyperlipidemia                              | \$11,858<br>(\$7 PMPM)      | 0.86%<br>(144)                                     |
| 1         | 1         | Cancer                                      | \$1,263,454<br>(\$625 PMPM) | 1.01%<br>(169)                                     |
| 7         | 13        | Fibromyalgia Chronic Pain and Fatigue       | \$71,321<br>(\$40 PMPM)     | 0.88%<br>(147)                                     |

# Chronic Conditions

PMPM view on Paid basis

Claims Cost By

Med+Rx Claims

Claim Cost Type

Amount Allowed

Rolling 12-Month Comparison  
May 2025 through Apr 2026

Division: All | Plan: All | Relationship: All | Status: ACTIVE | CCW Tier: Major | Condition Type: Extended Duration | # of Chronic Conditions: 1 or More Conditions

## SUMMARY DETAILS

Sort by

Members

Prevalence

All Members

Select any chronic condition to view members with the condition

| Curr Rank | Prev Rank | Chronic Condition                                       | Amount Allowed                | % Avg Prevalence (Avg Prevalence - All Members) |
|-----------|-----------|---|-------------------------------|---|
| 5         | 5         | Depression, Bipolar, or Other Depressive Mood Disorders | \$3,075,150<br>(\$1,191 PMPM) | 13.8%<br>(215)                                  |
| 1         | 1         | Hypertension  | \$4,153,188<br>(\$1,938 PMPM) | 11.4%<br>(179)                                  |
| 4         | 4         | Obesity   | \$3,176,872<br>(\$1,577 PMPM) | 10.8%<br>(168)                                  |
| 2         | 2         | Rheumatoid Arthritis/Osteoarthritis                     | \$3,999,090<br>(\$2,075 PMPM) | 10.3%<br>(161)                                  |
| 3         | 3         | Cancer  | \$3,406,965<br>(\$1,824 PMPM) | 10.0%<br>(156)                                  |
| 6         | 7         | Hyperlipidemia  | \$2,190,983<br>(\$1,287 PMPM) | 9.1%<br>(142)                                   |
| 7         | 6         | Diabetes  | \$1,766,749<br>(\$1,814 PMPM) | 5.2%<br>(81)                                    |
| 8         | 11        | Acquired Hypothyroidism                                 | \$1,384,045                   | 4.8%  |

## CHRONIC CONDITION MEMBERS DETAILS:

SELECTED: DEPRESSION, BIPOLAR, OR OTHER DEPRESSIVE MOOD DISORDERS

| Member ID | Amt Allowed | Amt Paid  | # Comorbidities | Months Sick |
|-----------|-------------|-----------|-----------------|-------------|
| 54774644  | \$364,438   | \$348,531 | 5               | 12          |
| 11303850  | \$278,123   | \$274,123 | 1               | 7           |
| 76568418  | \$236,985   | \$209,926 | 6               | 8           |
| 74228980  | \$133,236   | \$103,836 | 2               | 12          |
| 11304319  | \$93,877    | \$89,525  | 11              | 12          |
| 54772583  | \$85,031    | \$84,344  | 1               | 12          |
| 11302521  | \$78,379    | \$76,027  | 7               | 12          |
| 76488779  | \$74,056    | \$73,598  | 2               | 9           |
| 76389611  | \$62,964    | \$53,212  | 4               | 12          |
| 76574449  | \$59,533    | \$59,431  | 6               | 12          |
| 698766854 | \$57,124    | \$56,755  | 1               | 10          |
| 702297298 | \$49,005    | \$46,493  | 1               | 8           |
| 76402153  | \$47,294    | \$43,167  | 2               | 12          |
| 75350584  | \$46,780    | \$39,545  | 3               | 12          |
| 11302493  | \$44,295    | \$37,025  | 3               | 12          |
| 54772731  | \$43,458    | \$42,962  | 4               | 8           |
| 11303494  | \$34,513    | \$31,067  | 6               | 12          |
| 20018952  | \$33,604    | \$33,604  | 6               | 3           |
| 11303212  | \$33,589    | \$32,100  | 2               | 12          |
| 76390434  | \$29,543    | \$25,205  | 2               | 12          |
| 11303745  | \$29,254    | \$22,025  | 6               | 12          |
| 36579226  | \$28,741    | \$24,741  | 4               | 8           |

# Explore Supporting Data

## MENTAL HEALTH TRENDS OVER TIME Medical claims only. Rx details found below.

Network Flag

**23%** (434 / 1,923)  
 have mental health claims  
 Current Period thru Apr 2026


- ▲ 2.0% from prior period
- ▲ 5.7% from benchmark

**\$33**  
 Mental Health Allowed PMPM


% out-of-network: **0.7%**  
 Current Period thru Apr 2026

- ▲ 8.3% vs prior period

### Mental Health Medical Allowed PMPM



### Mental Health Telehealth



## MENTAL HEALTH DIAGNOSIS AND PROVIDER DETAILS Select a diagnosis or provider to filter

| Primary ICD Category                                 | Claimants | Telehealth Visits | Med Visits | ER Visits | Inpatient Visits | Allowed   |
|--|-----------|-------------------|------------|-----------|------------------|-----------|
| Neurodevelopmental disorders                         | 132       | 126               | 1,108      | 0         | 0                | \$244,053 |
| Anxiety and fear-related disorders                   | 219       | 372               | 1,460      | 5         | 0                | \$202,138 |
| Depressive disorders                                 | 112       | 290               | 645        | 3         | 2                | \$147,521 |
| Trauma- and stressor-related disorders               | 98        | 213               | 745        | 0         | 0                | \$89,160  |
| Bipolar and related disorders                        | 9         | 32                | 103        | 3         | 2                | \$24,847  |
| Opioid-related disorders                             | 5         | 4                 | 52         | 0         | 7                | \$18,910  |
| Schizophrenia spectrum and other psychotic disorders | 2         | 0                 | 14         | 0         | 1                | \$17,078  |
| Obsessive-compulsive and related disorders           | 6         | 24                | 36         | 0         | 0                | \$5,310   |
| Alcohol-related disorders                            | 6         | 7                 | 20         | 0         | 0                | \$5,034   |



# Forecast Future Costs

# Risk Over Time


[Click Here to Navigate to Target Cost Share by Risk Score Guide](#)

## Hylant Corporate Group, Inc.


Current Period: **May 2025 - Apr 2026** | **Month Paid** basis  
 Division: **All** | Plan: **All** | Person IDs: **All**

Continuously Enrolled Only

### High Risk Profile (4+ Risk Score)



### Risk Distribution Over Time



# All Historical High Risk Members - Currently Enrolled

## Hylant Corporate Group, Inc.

Current Period: **May 2025 - Apr 2026** | Month Paid basis

Division: **All** | Plan: **All** | Person IDs: **All**

Continuously Enrolled Only     
  Paid or Allowed     
  Claims Threshold     
 Risk Score  1 to 5

| Personid  | Relation | Gender | Age Group | Division 1 | Plan | Amt Allowed | Risk Score Heatmap |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|-----------|----------|--------|-----------|------------|------|-------------|--------------------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11303868  | E        | M      | 66+       | FW1        | A03  | \$531,593   | 5                  | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| 11303850  | C        | F      | 0-17      | IN3        | A04  | \$382,571   | 5                  | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| 54774644  | E        | F      | 51-65     | JX3        | A01  | \$364,438   | 5                  | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| 11304620  | E        | M      | 36-50     | 001        | A03  | \$268,613   | 5                  | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| 663682509 | E        | F      | 66+       | AN5        | A02  | \$241,307   | 1                  | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| 76568418  | E        | F      | 51-65     | T1E        | A02  | \$237,766   | 3                  | 3 | 3 | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| 11303126  | E        | F      | 51-65     | COB        | C04  | \$202,995   | 5                  | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| 11304041  | S        | M      | 66+       | T1H        | A03  | \$172,210   | 5                  | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| 74293690  | E        | F      | 18-35     | RIS        | A03  | \$160,378   | 3                  | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| 54769525  | E        | F      | 66+       | TO2        | A01  | \$154,241   | 4                  | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| 11303989  | C        | M      | 0-17      | AN5        | A03  | \$145,460   | 5                  | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |

# Risk Influenced Spend Predictor (validation)

Allowed 12 months following

24 Months Ending

December 2024

Trend Multiplier

6%

|            | Member Count | Current Period PMPY | Future 12 With Trend | Future PMPY |            | Avg Members | PMPY     | Amtallowed   |
|------------|--------------|---------------------|----------------------|-------------|------------|-------------|----------|--------------|
| 1          | 1,042        | \$3,003             | \$3,316,578          | \$3,183     | Null       | 0           |          | \$26,398     |
| 2          | 475          | \$8,329             | \$4,193,610          | \$8,829     | 1          | 1,082       | \$2,922  | \$3,161,181  |
| 3          | 142          | \$16,150            | \$2,430,823          | \$17,118    | 2          | 490         | \$6,864  | \$3,365,611  |
| 4          | 111          | \$25,437            | \$2,992,863          | \$26,963    | 3          | 150         | \$15,198 | \$2,278,379  |
| 5          | 47           | \$56,113            | \$2,795,536          | \$59,479    | 4          | 103         | \$26,128 | \$2,697,681  |
| Grand To.. | 1,817        |                     | \$15,729,411         |             | 5          | 48          | \$82,221 | \$3,946,593  |
|            |              |                     |                      |             | Grand To.. | 1,873       | \$8,261  | \$15,475,843 |


# Explore Supporting Data

## CURRENT HIGH RISK MEMBER PROFILE

High Risk and Low Spend  Low Spend Threshold\*

Current High Risk Member Spend  
*See information icon at the top for details on risk buckets*

|            |                           |
|------------|---------------------------|
|            | High Risk (4-5)           |
| Low Spend* | <b>9%</b><br>(11 / 127)   |
| High Spend | <b>91%</b><br>(116 / 127) |



## HIGH RISK LOW SPEND MEMBER DEMOGRAPHICS

View by:

### ICD / Rx Class of Current High Risk Low Spend Members

| Diagnosis / Therapeutic Code               | Claimants Current | Med Visits | Scripts |                     |
|--|-------------------|------------|---------|---------------------|
| Osteoarthritis                             | 9                 | 24         | 0       | \$9,681 (▲ 155%)    |
| Benign neoplasms                           | 2                 | 5          | 0       | \$4,525 (▲ 946%)    |
| Spondylopathies/spondyloarthropathy (inc.. | 2                 | 20         | 0       | \$4,130 (▼ 37%)     |
| Neoplasm-related encounters                | 9                 | 15         | 0       | \$3,160 (▼ 57%)     |
| Hepatitis                                  | 1                 | 9          | 0       | \$2,496 (▲ 51%)     |
| Circulatory signs and symptoms             | 2                 | 3          | 0       | \$1,978 ()          |
| Medical examination/evaluation             | 7                 | 13         | 0       | \$1,684 (▼ 55%)     |
| Heart failure                              | 1                 | 11         | 0       | \$1,461 ()          |
| Disorders of lipid metabolism              | 3                 | 3          | 0       | \$1,177 (▲ 1504%)   |
| MUSCULOSKELETAL THERAPY AGEN..             | 3                 | 0          | 3       | \$1,132 (▲ 342994%) |
| VASOPRESSORS                               | 1                 | 0          | 2       | \$1,110 (▲ 186%)    |
| Sleep wake disorders                       | 1                 | 7          | 0       | \$1,015 ()          |
| THYROID AGENTS                             | 3                 | 0          | 19      | \$998 (▲ 614%)      |

### High Risk Low Spend Demographic Breakdown *Select to filter*





# Provider Networks and Price Transparency

# Price Transparency Data Using Machine-Readable Files (MRFs)

- [Home](#)
- [Search Rates](#)
- [Hospital Rate Trends Beta](#)
- [Intelligence](#)
  - Completed Studies 37
  - [Create Market Study](#)
  - [Create Population Study](#)
  - [Create Provider Study](#)
  - [Census Summary Files](#)
- [Exported Searches 5](#)
- [Custom Weights 1](#)
- [Customer Service](#)
- [Resources](#)
  - [Release Notes](#)
  - [Sample Studies](#)
  - [User Guide](#)
- [Collapse](#)

[View All Plans](#)
[View Plans and Data Usability Ratings by State](#)
[View Plans and Data Usability Ratings by MSA](#)

| Plan                                    | Level       | Hospital Count | Last Update |
|---|-------------|----------------|-------------|
| Aetna Choice II POS                     | National    | 5199           | 2026-03-04  |
| Aetna Signature Administrators PPO      | National    | 5191           | 2026-03-04  |
| Aetna Open Access Managed Choice POS    | National    | 5060           | 2026-03-04  |
| UHC Choice Plus PPO                     | National    | 4151           | 2026-02-28  |
| BCBS Association BlueCard PPO           | National    | 4055           | 2026-02-28  |
| UHC Navigate HMO                        | National    | 3939           | 2026-02-28  |
| UHC Options PPO                         | National    | 3850           | 2026-02-28  |
| Cigna Open Access Plus (OAP) PPO        | National    | 3228           | 2026-02-28  |
| Cigna PPO                               | National    | 3139           | 2026-02-28  |
| Cigna LocalPlus EPO                     | National    | 2983           | 2026-02-28  |
| Centene Ambetter HMO                    | Multi-state | 2010           | 2026-01-27  |
| Dean Health PPO                         | National    | 792            | 2024-10-04  |
| First Health Network (Aetna TPA) PPO    | National    | 745            | 2026-03-04  |
| HCSC BCBSTX Blue Choice PPO             | TX          | 524            | 2026-02-18  |
| HCSC BCBSTX Blue Advantage Platinum HMO | TX          | 467            | 2026-02-17  |
| Cigna HMO                               | National    | 443            | 2026-02-28  |

### Claims Analysis

Upload a claims summary file for use in a Utilization Study. This study will compare the rates for utilized procedure codes for up to 4 plans.

[CREATE UTILIZATION STUDY](#)

### Market Based Analysis

Select up to 4 plans to compare rates paid in an MSA for 15 procedure code categories. The Data Usability Rating will help you select plans with sufficient rate data.

[CREATE MARKET STUDY](#)

### Provider Specific Analysis

Select up to 4 plans to analyze published price transparency rates for up to 10 providers.


[CREATE PROVIDER STUDY](#)

### Learn About Rates

Research market rates by payor/plan, billing codes and providers.

[SEARCH RATES](#)

# Using MRF Data to Evaluate Networks and Providers





# Q & A

[www.Hylant.com](http://www.Hylant.com)

## NEXT WEBINAR

Compliance Decoded: ***Actionable Insights for HR Leaders***, Thursday, July 16

Sign up: [hylant.com/insights/events](http://hylant.com/insights/events)